Fig. 6

Immune microenvironment evaluation between the low and high ZNF score groups. (A) The comparison of immunophenoscoring (IPS) scores. (B) Kaplan–Meier curves of OS of patients. The numbers of patients in low and high TIDE groups were 345 and 54, respectively (P = 0.0044, Log-rank test). (C) Survival analyses of patients with both ZNF score and TIDE using Kaplan–Meier curves. (P < 0.0001, Log-rank test). (D) The relative distribution of dysfunction score was compared between the low and high ZNF score groups. (E) The correlations between dysfunction and ZNF score in three ZNF clusters. (F) Kaplan–Meier curves of OS of patients. The numbers of patients in the low- and high-immune dysfunction groups were 268 and 131, respectively (P = 0.0085, Log-rank test). (G) Survival analyses of patients with both ZNF score and immune dysfunction using Kaplan–Meier curves. (P = 0.00029, Log-rank test). (H) The relative distribution of CD274 was compared between the low and high ZNF score groups. (I) The correlations between CD274 and ZNF score in three clusters. (J) Survival analyses stratified by both the ZNF score and CD274 using Kaplan–Meier curves. (P < 0.001, Log-rank test). (K) The relative distribution of CAF was compared between the low and high ZNF score groups. (L) Survival analyses stratified by both the ZNF score and CAF using Kaplan–Meier curves. (P < 0.0001, Log-rank test). TIDE tumor immune dysfunction and exclusion, CAF cancer-associated fibroblast. (*, **, ***, **** represent P < 0.05, P < 0.01, P < 0.001, P < 0.0001, respectively).